Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

Autor:	Pritchard-Jones, Kathy1 k.pritchard-jones@ucl.ac.uk, Bergeron, Christophe2, de Camargo, Beatriz3, van den Heuvel-Eibrink, Marry M.4, Acha, Tomas5, Godzinski, Jan6, Oldenburger, Foppe7, Boccon-Gibod, Liliane8, Leuschner, Ivo9, Vujanic, Gordan10, Sandstedt, Bengt11, de Kraker, Jan12, van Tinteren, Harm13, Graf, Norbert14, SIOP Renal Tumours Study Group (CORPORATE AUTHOR)
Zdroj:	Lancet. 9/19/2015, Vol. 386 Issue 9999, p1156-1164. 9p. 1 Diagram, 4 Charts, 1 Graph.
Databáze:	Business Source Ultimate
Externí odkaz:	Zobrazit plný text záznamu